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The adrenal glands produce a variety of hormones that play a key role in the regulation of blood pressure, electrolyte homeostasis,
metabolism, immune system suppression, and the body’s physiologic response to stress. Adrenal neoplasms can be asymptomatic or
can overproduce certain hormones that lead to different clinicalmanifestations.Oncocytic adrenal neoplasms are infrequent tumors
that arise from cells in the adrenal cortex and display a characteristic increase in the number of cytoplasmic mitochondria. Since
the rate-limiting step in steroidogenesis includes the transport of cholesterol across the mitochondrial membranes, in part carried
out by the 18-kDa translocator protein (TSPO), we assessed the expression of TSPO in a case of adrenal oncocytic neoplasm using
residual adrenal gland of the patient as internal control. We observed a significant loss of TSPO immunofluorescence expression
in the adrenal oncocytic tumor cells when compared to adjacent normal adrenal tissue. We further confirmed this finding by
employing Western blot analysis to semiquantify TSPO expression in tumor and normal adrenal cells. Our findings could suggest
a potential role of TSPO in the tumorigenesis of this case of adrenocortical oncocytic neoplasm.
1. Introduction
Adrenal oncocytic neoplasms (AON) are infrequent, usually
benign, nonfunctional tumors arising in the adrenal cortex
that occasionally display borderline or malignant clinical
courses. Histologic classification systems (i.e., Weiss system)
can usually predict aggressive behavior in regular (nononco-
cytic) adrenocortical neoplasms; however, histomorphologic
features inAONdonot always correlatewith clinical outcome
[1–3].
AON are composed of oncocytes, defined as large
eosinophilic cells approximately twice the size of a normal
adrenocortical cell with a large central nucleus, a promi-
nent nucleolus, and a characteristic abundant and granular
eosinophilic cytoplasm secondary to markedly increased
mitochondria [4]. Ultrastructurally, oncocytes are packed
with swollen mitochondria. Recent reports strongly support
an important role of abnormal steroidogenic events in the
pathogenesis of AON [5].
The 18-kDa translocator protein (TSPO) is a ubiquitous
mitochondrial nuclear-encoded protein that is upregulated in
steroidogenic organs like the adrenal glands and the gonads
[6, 7]. Its main function consists in facilitating the migration
of cholesterol from the outer to the inner mitochondrial
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Figure 1: Composite figure illustrating imaging, surgical, histologic, and ultrastructural findings. (a) Sagittal CT scan shows a large ovoid
mass (arrow) abutting the liver and the superior pole of the right kidney. (b) Surgical resection specimen highlights the bright yellow tumor
parenchyma as well as a portion of the patient’s residual adrenal gland (arrows). (c) Microscopic examination of adrenal oncocytic neoplasm
composed of large cells with abundant pink granular cytoplasm and irregular nuclei with prominent nucleoli (H&E, 20x).The insert highlights
the presence of areas displaying marked nuclear pleomorphism and atypia (H&E, 40x). (d) Transmission electron microscopy illustrating a
tumor cell at the center of the image with a large centrally located oval nucleus and abundant mitochondria occupying most of the cytoplasm.
H&E: hematoxylin and eosin.
membrane for its conversion into pregnenolone by the
cholesterol side-chain cleavage enzyme (CYP11A1) [8, 9].
Thus, transport of cholesterol through the mitochondrial
membranes is considered the rate-limiting step in steroido-
genesis [8]. Since conspicuous increase in intracytoplasmic
mitochondria is sine qua non of AON, we decided to
study TSPO expression in one case of AON by means of
immunofluorescence. Interestingly, we found a paradoxical
loss of TSPO expression in AON cells and confirmed the loss
of TPSO expression by Western blot semiquantification.
2. Case Presentation
A 49-year-old woman with no significant past medical or
surgical history other than sporadic migraines presented to
the emergency room at Jackson Memorial Hospital com-
plaining of a 2-week episode of abdominal distention and
flank pain. Initial examination revealed an otherwise normal
femalewith vital signswithin normal limits and discomfort in
the right flank, suspicious for a kidney stone. As part of her
initial workup, the patient had an abdominal CT scan that
revealed a 15 cm right adrenal mass (Figure 1(a)). No stones
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or signs of hydronephrosis or pyelonephritis were identified.
Laboratory workup, including serum determination of cor-
tisol (5.7mcg/dL, normal range: 4.3–22.4mcg/dL at 8 am),
aldosterone (<4.0 ng/dL, reference: ≤21 ng/dL), and adreno-
corticotropic hormone (12 pg/mL, reference: <47 pg/mL),
was unremarkable. The patient underwent surgical exci-
sion of the mass. The resected specimen consisted of a
well-encapsulated oval mass with a bright golden-yellow
parenchyma. The right adrenal gland was found adjacent to
themass (Figure 1(b)).Microscopic examination of the tumor
after formalin fixation demonstrated a neoplasm composed
of large oncocytic cells (Figure 1(c))with focal areas of nuclear
pleomorphism (Figure 1(c), insert).The presence of increased
intracytoplasmic mitochondria was confirmed by electron
microscopy (Figure 1(d)). Mitotic figures were not observed.
According to the proposed classification by Bisceglia et al. [1],
the tumor size and the absence of mitoses, necrosis, capsular,
and sinusoidal invasion indicate that this AON could harbor
borderline malignant potential. The patient’s postsurgical
course was unremarkable and no further treatment was
required. Currently, four years after surgery, the patient is
alive, tumor-free, and in her normal state of health.
2.1. TSPO Expression Assessed by Immunofluorescence Is
Markedly Decreased in Tumor Cells. In order to assess
the expression of TSPO we obtained additional unstained
slides from formalin-fixed paraffin-embedded (FFPE) tissue
including a representative section of the tumor with adjacent
normal adrenal gland (internal control) of the patient. Two
slides were deparaffinized after incubation at room tempera-
ture (RT, 24∘C) in xylene (twice for 10 minutes).The deparaf-
finized tissue sections were then rehydrated with a graded
series of ethanol (100%, 100%, 70%, 70%, and 50%) and
incubated in phosphate buffered saline (PBS) for 15 minutes
at RT. After incubation, slides were stained for TSPO by
immunofluorescence as previously described [10]. Primary
antibody to detect TSPO (FL-169, Santa Cruz Biotechnology,
Inc., Dallas, Texas, cat# 20120) was used at 1 : 75 dilution,
according to the manufacturer instructions. Fluorescent
HRP-conjugated secondary antibody (Alexa Flour-488 goat
anti-rabbit IgG (H+L)) was used at 1 : 200 dilutions.The slides
were reviewed with a Zeiss LSM510/UVAxiovert 200M con-
focal microscope (Carl Zeiss, Peabody, MA, USA). Multiple
images captured from tumor cells and normal adrenal gland
showed strong immunofluorescence positivity in the normal
adjacent adrenal gland (Figure 2(a)) and significant loss of
TSPO expression in the tumor cells (Figure 2(b)).
2.2. TSPO Semiquantification by Western Blot Confirms Par-
tial Loss of Expression in Tumor Cells. To more precisely
evaluate the loss of nuclear and cytoplasmic TSPO expression
in tumor cells and confirm the immunofluorescence findings,
we dissected mapped tumor and normal adrenal tissue from
FFPE unstained slides and performed immunoblots. Briefly,
FFPE tissue sections were deparaffinized by incubation at RT
in xylene (twice for 10 minutes). The deparaffinized tissue
sections were then rehydrated with a graded series of ethanol
(100%, 100%, 70%, 70%, and 50%) and incubated at RT in PBS
for 15 minutes. After incubation, tumor and normal adrenal
tissue were dissected off the slides and placed in two separate
plastic tubes. The tubes were pelleted at 16,000×g for 5 min-
utes, and the incubation/centrifugation steps were repeated
twice. Tissue samples were briefly air-dried in a fume hood.
The cell pellet was resuspended in 200𝜇l cold buffer A, con-
sisting of 10mMHEPES (pH 7.9), 10mMKCl, 0.1mMEDTA,
0.1mM EGTA, 1 𝜇M dithiothreitol (DTT), and a complete
protease inhibitor cocktail (Roche, Mannheim, Germany).
The pellet was then incubated on ice for 15 minutes to allow
cells to swell, after which 15 𝜇l of 10% NP-40 was added,
and the sample was vortexed thoroughly for 40 seconds and
centrifuged at 3,000 rpm for 3 minutes at 4∘C. The result-
ing supernatant was used for cytosolic TSPO measurement
(equal amount of protein, 12.4 𝜇g was loaded on an SDS-
polyacrylamide gel and Western blot analysis with TSPO
antibody was performed as described previously [11]) and the
pellet (nuclear fraction) was resuspended in 30 𝜇l cold buffer
B consisting of 20mM HEPES (pH 7.9), 0.4MNaCl, 1mM
EDTA, 1mM EGTA, 1 𝜇M DTT, and protease inhibitors.
The pellet was then incubated on ice and vortexed for 15
seconds every 2min for up to 15min. The nuclear extract
was then centrifuged at 13,000 rpm for 5 minutes at 4∘C.
Equal amounts of protein (21.6 𝜇g) from the supernatant
(containing the nuclear extract) were loaded and Western
blot analysis withTSPOantibodywas performed as described
above. The quality of the nuclear extract was analyzed
by propidium iodide staining, which indicated a purity of
92–96%. PrimaryTSPOantibody (SantaCruz Biotechnology,
Inc., Dallas, Texas, cat# 20120) was used at 1 : 1000 dilution.
Beta actin (ACTBD11B7, sc-81178, Santa Cruz Biotechnology,
Dallas, TX, USA) and lamin a/c (Cell Signaling Technology,
Beverly, MA, USA) antibodies were used at 1 : 5000 and
1 : 750, respectively. Anti-rabbit and anti-mouse secondary
antibodies (Vector Laboratories, Burlingame, CA, USA) were
used at 1 : 3000 dilution. Optical density of the bands was
determined with the Chemi-Imager (Alpha Innotech, San
Leandro, CA, USA) digital imaging system and the results
were quantified with the Sigma Scan Pro (Jandell Scientific,
San Jose, CA, USA) program as a proportion of the signal of
housekeeping protein bands (lamin a/c and 𝛽-actin, nuclear
and cytosolic markers, resp.).The experiment was performed
using 4 different tissue sections from the same sample and
the mean intensity of Western blot bands was subjected to
Tukey’s multiple comparison test. Statistical significance was
set at 𝑝 value = 0.05. As illustrated in Figures 2(a) and
2(b) (cytosolic fraction) and Figures 2(c) and 2(d) (nuclear
fraction), the representative semiquantitative immunoblots
from two different tumor sections show a significant decrease
in TSPO expression in the tumor sample of 72.4 and 72.8%
decrease in the cytosol and 77.1 and 76.8% decrease in the
nuclear fraction as compared to respective controls (𝑝 =
0.03).
3. Discussion
TheWeiss classification system for adrenocortical neoplasms
has been widely adopted and used to distinguish benign from
malignant tumors based on major (high mitotic rate, atypical
mitoses, and lymphovascular invasion) and minor criteria
4 Case Reports in Endocrinology
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Figure 2: Composite figure illustrating TSPO protein expression findings. (a) Expression of TSPO by immunofluorescence in normal adrenal
gland demonstrates diffuse immunofluorescence for TSPO protein, particularly in the zona glomerulosa (IF, 10x). (b) Diffuse loss of TSPO
expression assessed by immunofluorescence in adrenal oncocytic tumor cells (IF, 10x). Polyacrylamide gels of the experiments performed in
duplicate including normal adrenal cortex from the patient as internal control and tumor, normalized to 𝛽-actin for cytosolic extracts (c) and
lamin a/c for nuclear extracts (d) as housekeeping genes, show a noticeable decrease in the concentration of TSPO in tumor compared to the
patient’s normal adrenal gland. Western blot semiquantification bar graphs demonstrate 72.4 and 72.8% decrease in cytosolic and 77.1 and
76.8% decrease in nuclear TSPO expression as compared to respective controls. IF: immunofluorescence.
(large-size and increased weight, necrosis, capsular invasion,
and sinusoidal invasion) [3]. The presence of one major
criterion indicates malignancy, 1 to 4 minor criteria indicate
uncertain malignant potential (borderline), and the absence
of all major and minor criteria suggests a benign clinical
behavior [3]. While this classification system has been useful
in accurately predicting the biologic behavior of conventional
(nononcocytic) adrenocortical tumors, its use in the setting
Case Reports in Endocrinology 5
of AON is questionable. In a series of 10 cases of AON, the
Weiss system criteria were reviewed and modified to assess
its possible application to the oncocytic tumor variant. Using
this new grading system, 1 of the 10 cases had to be revised
to a final interpretation of malignant after tumor recurrence
[1]. In terms of imaging studies, a cutoff below 4-5 cm in
tumor size is used to suggest a benign behavior [12]. In cases
of oncocytic neoplasms, however, the size of the mass has
not demonstrated to reliably predict tumor behavior. Some
nonspecific findings such as fat concentration (almost all
malignant lesions are lipid poor) and lower attenuation (10
Hounsfield units or less) onCT scan have proven to be helpful
in making this differentiation [12, 13].
It has been extensively documented that these oncocytic
tumors display characteristic eosinophilic staining secondary
to the accumulation of mitochondria, which may occupy up
to 60% of the cytoplasm [4]. The increased concentration of
mitochondria is accompanied by a gradual compression and
sometimes disappearance of other cytoplasmic organelles
[14]. Because of the rarity of this type of adrenocortical
tumors and because immunohistochemical studies were not
consistently performed in most of the reported cases, their
immunophenotypic profile has not been completely char-
acterized [4, 15]. Nevertheless, studied cases demonstrate
diffuse positivity for vimentin, melan-A, synaptophysin, and
inhibin, while S-100 and chromogranin have been consis-
tently negative [15]. In some cases, immunopositivity with
an anti-mitochondrial antibody has been used to corroborate
that the tumors are truly oncocytic [16].
TSPO is found in the outer mitochondrial membrane of
almost every tissue in the body [17]. It is part of a complex of
proteins (i.e., StAR, PKA, ACBD3, andVDAC1) that function
together by forming a tansduceosome that facilitates choles-
terol transport from the outer to the inner mitochondrial
membrane for its conversion into pregnenolone by choles-
terol side-chain cleavage cytochrome P450 enzyme CYP11A1
[8, 9]. Recently, there has been controversy regarding the
critical role that TSPO plays in cellular homeostasis and
steroidogenesis. While some authors initially suggested a
crucial role based on experiments with TSPO knockout mice
whose embryos did not survive, others have replicated similar
experiments with different results [18–23]. Nevertheless, in
the realm of cancer, several studies have found an increased
TSPO protein expression in cancer cell lines and in tumor
biopsies of colon, breast, and prostate [19–21]. Moreover, in
the particular case of prostatic adenocarcinoma, TSPO pro-
tein expression was the highest in metastatic prostate cancer
samples where increased expression also correlated with dis-
ease progression [19]. More recently, TSPO has been shown
to be part of the mitochondria-to-nucleus signaling pathway
that modulates nuclear gene expression and TSPO levels
have been directly correlated with increased tumorigenicity
and/or malignancy, probably as a mechanism to promote
apoptosis and reduce tumorigenicity, thereby suggesting that
benign tumors do not have increased TSPO levels [6, 24–
26]. However, we have observed conventional adrenocortical
carcinomas with a wide range of TSPO expression, ranging
from no expression to markedly increased TSPO expression
[27]. Batarseh and Papadopoulos [17] consider TSPO as a
highly conserved, housekeeping gene that is expected to
remain permanently activated. Recently, TSPO gene has been
suggested as a novel target for cancer chemotherapy [22]. It
is possible that an altered regulation of the numerous cellu-
lar processes associated with mitochondria and cholesterol
transport could partially be responsible for the unrestrained
growth of tumors by mechanisms that remain unknown [17,
19, 23, 28–33].
While previous studies [32] have identified variable TSPO
expression in adrenocortical and other tumors, our study
represents the first description of TSPO expression in one
AON. The present case is unusual and interesting because
TSPO expression was paradoxically lost in the mitochondria
of the tumor cells when assessed by immunofluorescence
in comparison to the patient’s normal adrenal gland. When
these findings were further explored by direct semiquantifi-
cation of the presence of protein byWestern blot, up to a 77%
decrease in expression was confirmed between the tumor
and the patient’s normal adrenal cells in both cytoplasm and
nucleus. While our findings in this one particular case could
represent a coincidence, we believe that the fact that a tissue
section including the patient’s normal adrenal gland adjacent
to the tumor used to perform all tests argues otherwise,
particularly, because deparaffinization, immunofluorescence,
and Western blotting were performed on tumor and normal
cells at the same time on the same slide in several occasions.
Furthermore, preliminary results on the expression of TSPO
in adrenocortical neoplasms in a study performed by our
group employing immunohistochemistry demonstrated vari-
able TSPO expression in tumors arising in the adrenal cortex,
particularly adrenocortical carcinomas [27].
It is also possible that the increase in mitochondria
could be a compensatory phenomenon that could be in part
associated with tumor growth. While our findings could
indicate that loss of TSPO expression could play a role in
the tumorigenesis of this case of adrenocortical oncocytic
neoplasm potentially related to defective steroid biosynthesis,
additional studies including a larger number of cases of AON
are necessary to validate these findings and to determine the
role of TSPO in the pathogenesis of adrenocortical neoplasms
including AON.
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